Last reviewed · How we verify
Extract of Agaricus blazei Murill
Agaricus blazei Murill extract enhances immune function through polysaccharide and beta-glucan components that activate macrophages, natural killer cells, and other innate immune cells.
Agaricus blazei Murill extract enhances immune function through polysaccharide and beta-glucan components that activate macrophages, natural killer cells, and other innate immune cells. Used for Cancer (various types, under investigation in Phase 3), Immune support and immunomodulation.
At a glance
| Generic name | Extract of Agaricus blazei Murill |
|---|---|
| Sponsor | ECbiotech Taiwan |
| Drug class | Immunomodulator; natural product extract |
| Target | Pattern recognition receptors (Dectin-1, TLR); macrophage and NK cell activation |
| Modality | Small molecule |
| Therapeutic area | Oncology; Immunology |
| Phase | Phase 3 |
Mechanism of action
The extract contains bioactive polysaccharides, particularly beta-glucans, which are recognized by pattern recognition receptors on immune cells. These components stimulate macrophage activation, increase cytokine production (IL-2, TNF-α, IFN-γ), and enhance natural killer cell activity, thereby potentiating anti-tumor and immunomodulatory effects. The mechanism is primarily immunostimulatory rather than direct cytotoxic.
Approved indications
- Cancer (various types, under investigation in Phase 3)
- Immune support and immunomodulation
Common side effects
- Gastrointestinal disturbance
- Allergic reactions
- Fever
Key clinical trials
- The Effects of a Food Product Containing Mushroom Extracts (AndoSanTM) in Subjects with Colorectal Cancer-related Fatigue (NA)
- Andosan in Allergic and Asthma Patients (NA)
- Anti-inflammatory Effect of Agaricus Blazei Murill in Inflammatory Bowel Disease (IBD) (PHASE2, PHASE3)
- Agaricus Blazei Murill in Patients With Multiple Myeloma (PHASE2)
- Agaricus Blazei Murill (ABM) in Patients With Inflammatory Bowel Disease (IBD) (PHASE2)
- The Supplementary Effects of the Extract of Agaricus Blazei Murril on Type II Diabetes Mellitus (DM) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Extract of Agaricus blazei Murill CI brief — competitive landscape report
- Extract of Agaricus blazei Murill updates RSS · CI watch RSS
- ECbiotech Taiwan portfolio CI